Revitas Features Leading Analyst Firm in Webinar on Emerging Growth Pharma Challenges

Webinar will define strategies to help mid-market pharma manufacturers maximize profitability while maintaining compliance

PHILADELPHIA--()--Revitas, the leader in Enterprise Revenue Dynamics (ERD), will host a free webinar titled “A Survival Guide for Emerging Growth Pharmaceutical Companies” on Thursday, Dec. 13, 2012 at 1 p.m. EST. The webinar will feature analyst Eric Newmark, Program Director of Life Science Business Systems at IDC Health Insights, who will examine the biggest threats facing emerging growth life sciences companies and options that exist for juggling effective pricing execution with compliance requirements. In addition, Becky Holloway, Product Marketing Manager at Revitas, will be joined by a Revitas customer to share an inside look at how the company solved mid-market pain points, such as the pricing execution pressures resulting from rapid growth and an ever-increasing regulatory vice-grip, by adopting Revitas solutions for managing contracts, pricing, and compliance. Registration for the webinar is now open.

“Emerging growth pharmaceutical manufacturers operate in a complex industry that doesn’t favor the smaller players, which makes efficient contract management vital for staying competitive with the biggest manufacturers and adequately preparing for their own growth into larger enterprises,” said Newmark.

“Mid-market pharma companies face the same margin erosion and compliance issues as their larger counterparts but often lack the resources to solve them,” said Holloway. “As a result, these companies are at a significant competitive disadvantage. This webinar will explore these challenges and present a real-world example of how one mid-market company capitalized on Enterprise Revenue Dynamics to drive profitability and maintain regulatory compliance.”

This year, Revitas introduced the RevitasNOW offering to bring the core capabilities of its powerful ERD solution and industry best practices to mid-market pharmaceutical companies. By delivering this solution in the cloud with a low upfront capital expenditure, faster implementation, and ease of use, emerging growth companies gain a cost-effective SaaS solution following industry best practices for contract lifecycle management, pricing execution, and compliance automation.

Register today for “A Survival Guide for Emerging Growth Pharmaceutical Companies” or visit the Revitas website for more information.

About Revitas

Revitas, the leader in Enterprise Revenue Dynamics, delivers integrated solutions for contracts, pricing, and compliance that drive higher profitability and lower risk. Revitas empowers companies to optimize contract performance by defining, managing, and analyzing complex, multi-tier pricing incentives and enables positive proof of compliance with commercial, financial, and industry requirements. Powered by the secure, scalable, and standards-based Flex™ platform, Revitas™ applications speed time to market and improve visibility across B2B relationships. Hundreds of organizations across the most highly regulated and challenging industries leverage Revitas integrated solutions to save money, make money, and reduce risk. For details, visit www.revitasinc.com or http://blog.revitasinc.com/.

Contacts

Gregory FCA
Alicia Buonanno, 610-228-2096
Alicia@GregoryFCA.com

Release Summary

Revitas Features Leading Analyst Firm in Webinar on Emerging Growth Pharma Challenges

Contacts

Gregory FCA
Alicia Buonanno, 610-228-2096
Alicia@GregoryFCA.com